Cited 43 times in
Intermediate Dose 5-Fluorouracil-Induced Encephalopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.contributor.author | 성진실 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 정희철 | - |
dc.date.accessioned | 2015-06-10T13:01:35Z | - |
dc.date.available | 2015-06-10T13:01:35Z | - |
dc.date.issued | 2006 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/110872 | - |
dc.description.abstract | As an acute neurotoxicity, high dose 5-fluorouracil (5-FU)-induced encephalopathy is well-known, but encephalopathy associated with lower dose is rarely reported. Here, we report a case of a male with anal cancer who was treated with 5-FU 1000 mg/m2, continuous infusion for 5 days q4 weeks. At the second and the fourth cycles of chemotherapy, sudden confusion, cognitive dysfunction and disorientation occurred during 5-FU infusion. They were accompanied by hyperammonemia in the absence of focal neurological deficits or structural abnormalities. These symptoms completely disappeared and the serum ammonia level returned to normal after discontinuation of 5-FU and conservative care. In order to investigate a possible deficit of dihydropyrimidine dehydrogenase (DPD), we checked its mRNA level before and after treatment using real-time PCR. The patient's pre-treatment level was 80% compared with reference group, and it was elevated up to 187% of initial after 5-FU treatment, implying that that his encephalopathy may be 5-FU catabolite type rather than DPD deficiency. In conclusion, we report that encephalopathy can develop even with the dose of 5-FU lower than ever reported, and it should be considered as a differential diagnosis for proper management. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 55~59 | - |
dc.relation.isPartOf | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Antimetabolites, Antineoplastic/adverse effects* | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/adverse effects | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols/therapeutic use | - |
dc.subject.MESH | Anus Neoplasms/drug therapy | - |
dc.subject.MESH | Anus Neoplasms/pathology | - |
dc.subject.MESH | Cisplatin/administration & dosage | - |
dc.subject.MESH | Diagnosis, Differential | - |
dc.subject.MESH | Dose-Response Relationship, Drug | - |
dc.subject.MESH | Drug Administration Schedule | - |
dc.subject.MESH | Fluorouracil/adverse effects* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Hyperammonemia/complications | - |
dc.subject.MESH | Infusions, Intravenous | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Neoplasm Invasiveness | - |
dc.subject.MESH | Neurotoxicity Syndromes/diagnosis | - |
dc.subject.MESH | Neurotoxicity Syndromes/etiology* | - |
dc.title | Intermediate Dose 5-Fluorouracil-Induced Encephalopathy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Radiation Oncology (방사선종양학) | - |
dc.contributor.googleauthor | Yeon-A Kim | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Hye Jin Choi | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.contributor.googleauthor | Jin Sil Seong | - |
dc.contributor.googleauthor | Hei-Cheul Jeung | - |
dc.identifier.doi | 10.1093/jjco/hyi214 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01956 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03794 | - |
dc.relation.journalcode | J01207 | - |
dc.identifier.eissn | 1465-3621 | - |
dc.identifier.pmid | 16436463 | - |
dc.subject.keyword | 5-fluorouracil | - |
dc.subject.keyword | encephalopathy | - |
dc.subject.keyword | anal cancer | - |
dc.subject.keyword | hyperammonemia | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.alternativeName | Seong, Jin Sil | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Jeung, Hei Cheul | - |
dc.contributor.affiliatedAuthor | Seong, Jin Sil | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Jeung, Hei Cheul | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 36 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 55 | - |
dc.citation.endPage | 59 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, Vol.36(1) : 55-59, 2006 | - |
dc.identifier.rimsid | 54922 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.